Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

Andrew Blauvelt,Jacob P Thyssen,Emma Guttman-Yassky,Thomas Bieber,Esther Serra-Baldrich,Eric Simpson,David Rosmarin,Hany Elmaraghy,Eric Meskimen,Chitra R Natalie,Zhuqing Liu,Chenjia Xu,Evangeline Pierce,MaryAnn Morgan-Cox,Esther Garcia Gil,Jonathan I Silverberg

The British journal of dermatology（2023）

引用 10|浏览7

暂无评分

摘要

After a 16-week induction period with lebrikizumab Q2W, lebrikizumab Q2W and Q4W maintained similar improvement of the signs and symptoms of moderate-to-severe AD, with a safety profile consistent with previously published data.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要